Canada

Search form

News & Events

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2016 on Wednesday, November 2, 2016

MARLBOROUGH, Mass., Oct. 3, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2016 on Wednesday, November 2, 2016, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Date: Oct 17, 2016

--Ceremony Marks the Start of Hologic's Month-Long Awareness Campaign in Support of the Genius™ 3D Mammography™ Exam--

MARLBOROUGH, Mass., Sept. 30, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that breast cancer survivor and Grammy Award-winner Sheryl Crow will join Steve MacMillan, the Company's Chairman, President and Chief Executive Officer, to ring the Nasdaq Opening Bell on October 3, in conjunction with the start of Breast Cancer Awareness Month.

Date: Oct 17, 2016

MARLBOROUGH, Mass., Sept. 8, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for the company's Aptima® Zika virus diagnostic assay to be used with urine samples (collected alongside patient-matched serum or plasma specimens).

Date: Oct 17, 2016

--Low Dose 3D MAMMOGRAPHY™ Exams Maintain Invasive Cancer Detection Rates and Reduce Unnecessary Patient Recalls--

MARLBOROUGH, Mass., August 17, 2016 -- Hologic Inc. (Nasdaq: HOLX) announced today that a study by University of Pennsylvania researchers, published online in advance of print by Radiology, shows that Low Dose 3D MAMMOGRAPHY™ exams with C-View™ software are comparable to traditional Genius™ 3D MAMMOGRAPHY™ exams, with similar overall and invasive breast cancer detection, as well as recall rates.[i]

Date: Sep 01, 2016

--Tomosynthesis Screening Combined with Either Traditional 2D or Hologic’s C-View™ 2D Provides Comparable Results--
MARLBOROUGH, Mass., August 9, 2016 -- Hologic Inc. (Nasdaq: HOLX) announced today that study results published online in advance of print by Lancet Oncology conclude that Low Dose 3D MAMMOGRAPHY™ exams with C-View™ software are comparable to traditional breast tomosynthesis screening exams in detecting more invasive breast cancers than 2D mammography alone.[i]

Date: Aug 17, 2016

Hologic Applauds NCCN for Recognizing the Comprehensive Body of Literature Supporting the Use of 3D MAMMOGRAPHY™ Exams for Breast Cancer Screening
MARLBOROUGH, Mass., Aug. 1, 2016 /PRNewswire/ -- Hologic Inc. (Nasdaq: HOLX) announced today that new guidelines published by the National Comprehensive Cancer Network (NCCN) recommend that physicians consider breast tomosynthesis exams as an option for their patients' annual breast cancer screening.1

Date: Aug 17, 2016

MARLBOROUGH, Mass., July 1, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2016 on Wednesday, July 27, 2016, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Date: Aug 17, 2016

MARLBOROUGH, Mass., July 5, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No.

Date: Aug 02, 2016

Aptima® HBV Quant Assay Joins Tests for HIV-1 and HCV on the Fully Automated Panther Instrument

Marlborough, Mass., December 10, 2015 – Hologic, Inc. (Nasdaq: HOLX) has earned CE-IVD certification for its Aptima HBV Quant assay on the fully automated Panther® instrument, the Company announced today.

This assay expands the European virology menu available on the Panther system, which previously included the Aptima HIV-1 Quant Dx and Aptima HCV (hepatitis C virus) Quant Dx viral load assays. 

Date: Dec 10, 2015

-- Systems Increase Ease of Use and Productivity for Cytology Labs --                                

MARLBOROUGH, Mass., November 10, 2015 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that gynecological samples can now be processed on the ThinPrep 5000 Processor and the ThinPrep 5000 with Autoloader System, providing labs with state-of-the-art automation and productivity for preparing cytology slides. 

Date: Nov 11, 2015

CE‐IVD Certification of Aptima® HCV Quant Dx Assay on Panther® System Continues Company’s Expansion into Virology Testing Market

Marlborough, Mass., 20 October, 2015 – Hologic (NASDAQ: HOLX) has earned CE‐IVD certification for its Aptima® HCV (hepatitis C virus) Quant Dx assay on the fully automated Panther® system, the Company announced today.

Date: Oct 20, 2015

-- By Focusing on Older Data, Government Task Force Underestimates

the Benefits that Newer Technologies Like Breast Tomosynthesis Offer Women --

Date: Apr 22, 2015

The Aptima HPV assay accurately detects the types of human papillomavirus most likely to cause cervical cancer

Date: Mar 24, 2015

Improved sample quality, workflow efficiencies and flexibility drive transition to Hologic platform

Date: Mar 05, 2015

By reducing unnecessary patient recalls and avoiding later-stage treatment, researchers estimate that the adoption of the new breast cancer screening technology can significantly reduce insurer costs

Date: Jan 13, 2015

The new assay is certified for both diagnosis and viral load monitoring on the Panther system

Date: Nov 30, 2014

UGAP joins UNICANCER and AP-HP in awarding public tenders specifying Hologic mammography solutions for hospitals in France

Date: Nov 12, 2014

Hologic has sold the Sentinelle product line of advanced MRI coils to Invivo, a Philips business (www.invivocorp.com/SentinellebyInvivo.php).

Date: Sep 30, 2014

Six-year contract with large Belgium lab includes the purchase of Hologic ThinPrep test and automated processing equipment

Date: Jun 27, 2013

New contracts include usage of ThinPrep Pap Test and Imaging System in all NHS cytology laboratories in Scotland

Date: Jun 25, 2013

Nucleic acid amplified tests used to detect high-risk strains of human papillomavirus

Date: Apr 04, 2013

APTIMA HPV assay accurately detects the HPV types most likely to progress to cervical cancer

Date: Mar 19, 2013

Unlike tests involving culture-based methods, the new Prodesse ProGastro SSCS Assay allows labs to test the common bacterial pathogens associated with in hours instead of days

Date: Jan 22, 2013